AstraZeneca blames trial design for Phase 3 failure of bone disease drug - Endpoints News
Source: Endpoints News ·
AstraZeneca blames trial design for Phase 3 failure of bone disease drug Endpoints NewsEfzimfotase alfa showed numerical improvement in Six-Minute Walk Test achieving mean difference of 17.05 metres vs placebo in treatment-naïve adolescents and adults with hypophosphatasia at week 25 in HICKORY Phase III trial AstraZenecaAstraZeneca pins bone disease drug’s Phase III failure on high placebo…